샘플 요청 목록

 카트 문의
시장보고서
상품코드
1528025

세계의 성장 인자(혈액 및 조직) 시장

Growth Factors (Blood and Tissue)
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 223 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

성장 인자(혈액 및 조직) 시장은 2030년까지 1,015억 달러에 도달할 전망입니다.

2023년에 584억 달러로 추정된 성장 인자(혈액 및 조직) 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 8.2%로 성장하고, 2030년에는 1,015억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 인터페론은 복합 연간 성장률(CAGR) 9.9%로 성장을 지속하여 분석 기간 종료 시 782억 달러에 이를 것으로 예상됩니다. 콜로니 자극 인자(Colony Stimulating Factors) 분야의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 마이너스 1.5%로 추정됩니다.

미국 시장은 추정 153억 달러, 중국은 복합 연간 성장률(CAGR) 12.7%로 성장할 것으로 예측됩니다.

미국 성장 인자(혈액 및 조직) 시장은 2023년 153억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 262억 달러 규모에 이를 것으로 예측되며 예측 기간 동안 복합 연간 성장률(CAGR)은 12.7%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 4.0%와 7.4%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 5.0%로 성장할 것으로 예측됩니다.

세계 성장 인자(혈액 및 조직) 시장 - 주요 동향과 촉진요인 요약

성장 인자란 무엇인가, 왜 의료의 진보에 필수적인가?

성장 인자는 자연적으로 발생하는 단백질 또는 호르몬이며, 세포 증식, 분화, 조직 복구를 포함한 다양한 세포 과정의 조절에 매우 중요한 역할을 합니다. 이러한 생물학적 분자는 부상과 질병에 대한 신체의 반응에 중요하며 손상된 조직의 복구와 재생을 촉진합니다. 상피성장 인자(EGF), 섬유아세포성장 인자(FGF), 혈관내피성장 인자(VEGF) 등의 성장 인자는 치료 가능성에 대해 광범위하게 연구되고 있습니다. 임상 장소에서 성장 인자는 상처 치유를 촉진하고, 이식 조직의 성장을 지지하고, 재생 의료 치료의 결과를 개선하기 위해 이용됩니다. 이러한 성장 인자가 신체에 내재된 수복 기구를 자극하는 능력은 만성 상처와 화상에서 심혈관 질환 및 정형외과적 손상에 이르기까지 다양한 병리를 치료하는데 있어서 귀중한 것이 되고 있습니다.

기술 혁신은 의료에서의 성장 인자의 사용을 어떻게 촉진하고 있는가?

기술의 진보는 의료에서 성장 인자의 응용을 크게 뒷받침하고 치료 가능성과 효능을 확대하고 있습니다. 생명공학과 유전공학의 최근 기술 혁신은 재조합성장 인자의 대량생산을 가능하게 하여 보다 입수가 용이하고 비용효과가 높아지고 있습니다. 게다가 나노입자와 하이드로겔과 같은 첨단 전달 시스템의 개발은 부상 부위로의 성장 인자의 표적 전달과 지속적인 방출을 개선하고 치료 효과를 높입니다. 조직 공학과 재생 의학도 이러한 진보의 이점을 얻고 있으며 성장 인자는 조직의 재생과 복구를 촉진하기 위해 발판과 생체 재료에 통합되어 있습니다. 이러한 기술적 진보는 성장 인자의 효능을 향상시킬 뿐만 아니라 복잡한 의료 치료 및 치료에 응용할 수 있는 새로운 가능성을 열어 줍니다.

왜 다양한 의료 분야에서 성장 인자 수요가 급증하고 있는가?

성장 인자의 치료 효과에 대한 인식이 높아짐에 따라 다양한 의료 분야에서 수요가 급증하고 있습니다. 피부과학에서 성장 인자는 피부 회춘을 촉진하고 노화의 징후를 줄이기 위해 미용 시술에 사용됩니다. 정형외과에서는 골절과 연조직 손상의 치유를 촉진하는 데 중요한 역할을합니다. 심장혈관 분야에서도 혈관 신생을 촉진하고 허혈 상태의 환자의 혈류를 개선하기 위해 성장 인자가 사용됩니다. 또한 성장 인자는 줄기세포의 배양이나 이식용 생체조직의 개발에 사용되는 재생의료 분야에도 필수적입니다. 이러한 다양한 의료 분야에서 성장 인자의 응용을 확대하면 현대 건강 관리에서 성장 인자의 중요성을 강조하고 잠재력을 극대화하기 위해 끊임없는 연구 개발 노력을 촉진하고 있습니다.

성장 인자 시장의 성장을 가속하는 요인은 무엇인가?

성장 인자 시장의 성장은 여러 요인에 의해 견인됩니다. 생명공학과 유전공학의 기술적 진보로 재조합 성장 인자의 생산이 보다 효율적이고 비용 효율적이 되어, 이용가능성이 높아지고 있습니다. 당뇨병이나 심혈관 질환 등 조직의 수리와 재생을 필요로 하는 만성 질환이나 병태의 유병률의 상승이 성장 인자 수요에 박차를 가하고 있습니다. 게다가 성장 인자에 크게 의존하는 재생 의학 및 조직 공학적 접근법의 채택이 증가하고 있는 것도 시장 성장을 가속하고 있습니다. 피부 회춘과 상처 치유를 위해 성장 인자를 이용하는 미용 및 피부과 수술 증가는 시장을 더욱 확대하고 있습니다. 게다가 성장 인자의 효능과 표적 작용을 높이는 혁신적인 약물전달 시스템의 개척은 대량의 투자를 불러들여 시장의 확대를 촉진하고 있습니다. 고급 치료 용도에 대한 정부의 자금 지원 및 지원 규제 프레임워크은 성장 인자 시장의 성장을 가속하는데 중요한 역할을 합니다.

조사 대상 기업 예(주목 101사)

  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocon Ltd.
  • Biogen, Inc.
  • Biopharm GmbH
  • Bolder BioTechnology, Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Genentech, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck Serono
  • PeproTech, Inc.
  • Reliance GeneMedix Plc
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Scil Proteins GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴 아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴 아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH

Global Growth Factors (Blood and Tissue) Market to Reach US$101.5 Billion by 2030

The global market for Growth Factors (Blood and Tissue) estimated at US$58.4 Billion in the year 2023, is expected to reach US$101.5 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2023-2030. Interferons, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$78.2 Billion by the end of the analysis period. Growth in the Colony Stimulating Factors segment is estimated at -1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$15.3 Billion While China is Forecast to Grow at 12.7% CAGR

The Growth Factors (Blood and Tissue) market in the U.S. is estimated at US$15.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$26.2 Billion by the year 2030 trailing a CAGR of 12.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Growth Factors (Blood and Tissue) Market - Key Trends and Drivers Summarized

What Are Growth Factors and Why Are They Crucial for Medical Advancements?

Growth factors are naturally occurring proteins or hormones that play a pivotal role in regulating various cellular processes, including cell proliferation, differentiation, and tissue repair. These biological molecules are critical in the body's response to injury and disease, facilitating the repair and regeneration of damaged tissues. Growth factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) are extensively studied for their therapeutic potential. In clinical settings, growth factors are utilized to enhance wound healing, support the growth of grafted tissues, and improve the outcomes of regenerative medicine procedures. The ability of these factors to stimulate the body's intrinsic repair mechanisms makes them invaluable in treating a wide range of medical conditions, from chronic wounds and burns to cardiovascular diseases and orthopedic injuries.

How Are Technological Innovations Enhancing the Use of Growth Factors in Medicine?

Technological advancements are significantly boosting the application of growth factors in medicine, expanding their therapeutic potential and efficacy. Recent innovations in biotechnology and genetic engineering have enabled the large-scale production of recombinant growth factors, making them more accessible and cost-effective. Additionally, the development of advanced delivery systems, such as nanoparticles and hydrogels, has improved the targeted delivery and sustained release of growth factors at the injury site, enhancing their therapeutic impact. Tissue engineering and regenerative medicine have also benefited from these advancements, with growth factors being incorporated into scaffolds and biomaterials to promote tissue regeneration and repair. These technological strides not only enhance the effectiveness of growth factors but also open up new possibilities for their application in complex medical procedures and treatments.

Why Is There a Surge in Demand for Growth Factors in Various Medical Fields?

The increasing recognition of the therapeutic benefits of growth factors has led to a surge in their demand across various medical fields. In dermatology, growth factors are used in cosmetic procedures to stimulate skin rejuvenation and reduce signs of aging. In orthopedics, they play a crucial role in accelerating the healing of bone fractures and soft tissue injuries. The cardiovascular field also leverages growth factors to promote angiogenesis and improve blood flow in patients with ischemic conditions. Moreover, growth factors are integral to the field of regenerative medicine, where they are used to cultivate stem cells and develop bioengineered tissues for transplantation. The expanding application of growth factors in these diverse medical domains underscores their importance in modern healthcare and drives continuous research and development efforts to explore their full potential.

What Factors Are Driving the Growth in the Growth Factors Market?

The growth in the growth factors market is driven by several factors. Technological advancements in biotechnology and genetic engineering are making the production of recombinant growth factors more efficient and cost-effective, thereby increasing their availability. The rising prevalence of chronic diseases and conditions that require tissue repair and regeneration, such as diabetes and cardiovascular diseases, is spurring demand for growth factors. Additionally, the increasing adoption of regenerative medicine and tissue engineering approaches, which rely heavily on growth factors, is propelling market growth. The growing number of cosmetic and dermatological procedures that utilize growth factors for skin rejuvenation and wound healing further expands the market. Moreover, the development of innovative drug delivery systems that enhance the efficacy and targeted action of growth factors is attracting significant investments and fostering market expansion. Government funding and supportive regulatory frameworks for advanced therapeutic applications also play a crucial role in driving the growth of the growth factors market.

Select Competitors (Total 101 Featured) -

  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocon Ltd.
  • Biogen, Inc.
  • Biopharm GmbH
  • Bolder BioTechnology, Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Genentech, Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck Serono
  • PeproTech, Inc.
  • Reliance GeneMedix Plc
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Scil Proteins GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Growth Factors (Blood and Tissue) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Chronic Diseases Spurs Demand for Growth Factors
    • Rise in Regenerative Medicine Expands Addressable Market Opportunity
    • Innovations in Drug Delivery Systems Strengthen Business Case for Growth Factors
    • Advancements in Biotechnology Propel Growth in Growth Factors Market
    • Growing Adoption of Tissue Engineering Generates Demand for Growth Factors
    • Integration of Growth Factors in Orthopedic Treatments Propels Market Expansion
    • Increasing Application of Growth Factors in Cardiovascular Therapies
    • Advances in Genetic Engineering Accelerate Demand for Recombinant Growth Factors
    • Expansion of Stem Cell Research Throws the Spotlight on Growth Factors
    • Technological Innovations in Biomaterials Propel Growth in the Use of Growth Factors
    • Rising Demand for Growth Factors in Wound Healing and Burn Treatment Expands Market Scope
    • Impact of Aging Population on Demand for Growth Factors in Age-Related Therapies
    • Personalized Medicine and Its Influence on Growth Factors Market Trends
    • Here's the Story on Growth Factors in Neurological Repair and Regeneration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Growth Factors (Blood and Tissue) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Erythropoietins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Interleukins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Interleukins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • JAPAN
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • CHINA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • EUROPE
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • FRANCE
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • GERMANY
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • INDIA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030
  • AFRICA
    • Growth Factors (Blood and Tissue) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Growth Factors (Blood and Tissue) by Growth Factor - Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Growth Factors (Blood and Tissue) by Growth Factor - Percentage Breakdown of Value Sales for Interferons, Colony Stimulating Factors, Erythropoietins, Interleukins and Other Growth Factors for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제